EpiVario, Inc.
Biotechnology ResearchPennsylvania, United States2-10 Employees
EpiVario, Inc. is a preclinical biotechnology company focused on memory-related neuropsychiatric disorders, including PTSD and addiction. Grounded in neuroepigenetics, its research centers on a metabolic enzyme that functions in the neuron's nucleus to activate genes linked to long-term memory, a mechanism implicated in the consolidation of trauma-related fear and drug craving. By intervening in these memory processes, the company aims to develop therapies for conditions driven by memory reconsolidation, starting with nicotine addiction. Headquartered in Philadelphia, Pennsylvania, EpiVario was founded by University of Pennsylvania epigeneticists Dr. Shelley Berger and Dr. Philipp Mews, who bring decades of combined experience in the field. The organization operates with a small team and maintains an emphasis on intellectual property, with PCT and U.S. patents pending related to a novel approach to targeting the ACSS2 gene. A recent development is the appointment of Chris Cashman as an independent director to the board in October 2024.
1-888-653-2347 
support@leadiq.com 
